Audion News

  • Audion Therapeutics and REGAIN Consortium Announce Positive Phase I Results in Patients with Sensorineural Hearing Loss

        AMSTERDAM, The Netherlands, February 05, 2019 The REGAIN consortium, led by Audion Therapeutics BV, a company dedicated to the development of therapeutics for hearing loss, today reports positive results from its Phase I multiple ascending dose, open-label safety study of the Notch Inhibitor LY3056480 in 15 patients with mild to moderate sensorineural hearing loss (SNHL). LY3056480 mediated Notch inhibition is aimed at regeneration of inner ear sensory hair cells that are lost with advancing age. The study was conducted at University College London and University College London Hospitals and focused on the safety and tolerability of LY3056480 in patients […]

  • Audion and REGAIN Horizon 2020 partners will present at the 41st ARO meeting February 9-14 2018

    Abstract Title: A small molecule regenerative therapy for adult onset sensorineural hearing loss; the REGAIN Horizon 2020 consortium approach. Time and date to be announced on the ARO website.

  • Audion Therapeutics Raises Funds to Advance the Development of Hearing Loss Treatment

    AMSTERDAM, The Netherlands, Sept. 7, 2015 (GLOBE NEWSWIRE) — Audion Therapeutics announced today that it has received a 2.5 million Euro Series B investment from INKEF Capital, a Netherlands based venture capital firm. In addition, Audion announced that, together with a strong international consortium of development partners, it was awarded a 5.8 million Euro grant through the Horizon 2020 program. The combined funds of 8.3 million Euro enable Audion to progress its lead program targeting sensorineural hearing loss to clinical Proof of Concept. Rolf Jan Rutten, CEO of Audion commented on these important milestones: “The investment from INKEF Capital and the receipt […]

  • Audion Announces Investment and Licensing Deal With Lilly To Develop Hearing Loss Treatments

    Amsterdam, the Netherlands, February 10, 2014 Audion Therapeutics announced today that it has received a Series A investment from Eli Lilly and Company to enable the company to progress its programs targeting sensorineural hearing loss. As part of the investment, the parties also entered into a licensing agreement that gives Audion the rights to certain Lilly compounds that can be developed to potentially treat hearing loss by hair cell regeneration. Under the terms of the license, Lilly has an option to reacquire these rights upon successful clinical Proof of Concept. Financial terms were not disclosed. Following the investment, Mr. Shaun Hawkins, […]

© Copyright Audion Therapeutics BV 2019. All rights reserved.